Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.170
-0.040 (-3.31%)
Aug 29, 2025, 4:00 PM - Market closed
Lineage Cell Therapeutics Employees
As of December 31, 2024, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees increased by 2 or 2.67% compared to the previous year.
Employees
77
Change (1Y)
2
Growth (1Y)
2.67%
Revenue / Employee
$141,740
Profits / Employee
-$531,299
Market Cap
267.18M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 77 | 2 | 2.67% |
Dec 31, 2023 | 75 | -3 | -3.85% |
Dec 31, 2022 | 78 | 17 | 27.87% |
Dec 31, 2021 | 61 | 6 | 10.91% |
Dec 31, 2020 | 55 | 0 | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LCTX News
- 5 days ago - Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss - Business Wire
- 18 days ago - Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 26 days ago - Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 - Business Wire
- 27 days ago - Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury - Business Wire
- 2 months ago - Two Biotech Stocks Poised For Big Moves On Monday - Benzinga
- 2 months ago - OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025 - Business Wire
- 3 months ago - Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium - Business Wire